NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
01/15/2025
Back to search
Official data from USPTO
US PHARMACEUTICAL CORPORATION
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
US PHARMACEUTICAL CORPORATION
ST13
US500000076370833Class
5
Filing
76370833
Registration
2890741
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
02/04/2025
Trademark type
Word
Nice classes
5
Filing date
02/13/2002
Registration date
10/05/2004
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/15/2025
Last transaction
02/04/2025
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
First use anywhere
1981-08-00
First use in commerce
1981-08-00
Drawing code
1
Owner type
03
Owner location
Decatur, GA
Examiner
DEFORD, JEFFREY
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
U. C. (pessoa física)
Representatives
Joel R. Feldman Greenberg Traurig, LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Vitamins and prescription and over the counter drugs for use in the treatment of iron deficiency and related diseases and for the treatment of osteo and rheumatoid arthritisprenatal preparationsfor use in the treatment of iron deficiency anemia and anemia associated with vitamin and mineral deficiencypreparations for the relief of pain or osteo and rheumatoid arthritispreparations for the treatment of allergies and the alleviation of cough and cold symptoms
Publications
History of USPTO decisions and trademark events.
31 publications found
RNL2
REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
01/15/2025
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
01/15/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/15/2025
E89R
TEAS SECTION 8 & 9 RECEIVED
09/25/2024
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
10/05/2023
NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
09/18/2014
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
09/18/2014
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
09/18/2014
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/16/2014
E89R
TEAS SECTION 8 & 9 RECEIVED
09/03/2014
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
08/08/2012
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
08/08/2012
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
01/03/2010
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/03/2010
E815
TEAS SECTION 8 & 15 RECEIVED
12/22/2009
R.PR
REGISTERED-PRINCIPAL REGISTER
10/05/2004
PUBO
PUBLISHED FOR OPPOSITION
07/13/2004
NPUB
NOTICE OF PUBLICATION
06/23/2004
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/30/2004
CNEA
EXAMINERS AMENDMENT MAILED
04/29/2004
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
03/09/2004
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/09/2004
CFIT
CASE FILE IN TICRS
12/24/2003
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/11/2003
PAPER RECEIVED
12/11/2003
CNFR
FINAL REFUSAL MAILED
08/04/2003
PAPER RECEIVED
12/04/2002
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/03/2002
CNRT
NON-FINAL ACTION MAILED
06/03/2002
DOCK
ASSIGNED TO EXAMINER
05/09/2002
Continuous trademark protection
Get notified about every new filing that threatens US PHARMACEUTICAL CORPORATION or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.